|
1
|
Capel B, Swain A, Nicolis S, Hacker A,
Walter M, Koopman P, Goodfellow P and Lovell-Badge R: Circular
transcripts of the testis-determining gene Sry in adult mouse
testis. Cell. 73:1019–1030. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Vo JN, Cieslik M, Zhang Y, Shukla S, Xiao
L, Zhang Y, Wu YM, Dhanasekaran SM, Engelke CG, Cao X, et al: The
landscape of circular RNA in cancer. Cell. 176:869–881.e13. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yang Y, Luo D, Shao Y, Shan Z, Liu Q, Weng
J, He W, Zhang R, Li Q, Wang Z and Li X: circCAPRIN1 interacts with
STAT2 to promote tumor progression and lipid synthesis via
upregulating ACC1 expression in colorectal cancer. Cancer Commun
(Lond). 43:100–122. 2023. View Article : Google Scholar
|
|
4
|
Wu H, Wang B, Wang L and Xue Y: circular
RNAs 0000515 and 0011385 as potential biomarkers for disease
monitoring and determining prognosis in pancreatic ductal
adenocarcinoma. Oncol Lett. 23:562022. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ling S, He Y, Li X, Hu M, Ma Y, Li Y, Lu
Z, Shen S, Kong B, Zou X, et al: CircRHOT1 mediated cell
proliferation, apoptosis and invasion of pancreatic cancer cells by
sponging miR-125a-3p. J Cell Mol Med. 24:9881–9889. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Li C, Zhang J, Yang X, Hu C, Chu T, Zhong
R, Shen Y, Hu F, Pan F, Xu J, et al: hsa_circ_0003222 accelerates
stemness and progression of non-small cell lung cancer by sponging
miR-527. Cell Death Dis. 12:8072021. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Peng L, Sang H, Wei S, Li Y, Jin D, Zhu X,
Li X, Dang Y and Zhang G: circCUL2 regulates gastric cancer
malignant transformation and cisplatin resistance by modulating
autophagy activation via miR-142-3p/ROCK2. Mol Cancer. 19:1562020.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cheng D, Wang J, Dong Z and Li X:
Cancer-related circular RNA: Diverse biological functions. Cancer
Cell Int. 21:112021. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wang M, Yu F, Li P and Wang K: Emerging
function and clinical significance of exosomal circRNAs in cancer.
Mol Ther Nucleic Acids. 21:367–383. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Memczak S, Jens M, Elefsinioti A, Torti F,
Krueger J, Rybak A, Maier L, Mackowiak SD, Gregersen LH, Munschauer
M, et al: Circular RNAs are a large class of animal RNAs with
regulatory potency. Nature. 495:333–338. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wu H, Zhao X, Wang J, Jiang X, Cheng Y, He
Y, Sun L and Zhang G: Circular RNA CDR1as alleviates
Cisplatin-based chemoresistance by suppressing MiR-1299 in ovarian
cancer. Front Genet. 12:8154482021. View Article : Google Scholar
|
|
12
|
Yu S, Wang M, Zhang H, Guo X and Qin R:
Circ_0092367 inhibits EMT and gemcitabine resistance in pancreatic
cancer via regulating the miR-1206/ESRP1 Axis. Genes (Basel).
12:17012021. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yamada M, Tanaka K, Yamamoto K, Matsumoto
H, Yamasaki M, Yamashita K, Makino T, Saito T, Yamamoto K,
Takahashi T, et al: Association between circ_0004365 and cisplatin
resistance in esophageal squamous cell carcinoma. Oncol Lett.
26:4672023. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mao S, Cheng Y, Huang Y, Xiong H and Gong
C: Comprehensive analysis of the exosomal circRNA-miRNA-mRNA
network in breast cancer. J Gene Med. 25:e35002023. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li Y, Zheng Q, Bao C, Li S, Guo W, Zhao J,
Chen D, Gu J, He X and Huang S: Circular RNA is enriched and stable
in exosomes: A promising biomarker for cancer diagnosis. Cell Res.
25:981–984. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Huang XJ, Wang Y, Wang HT, Liang ZF, Ji C,
Li XX, Zhang LL, Ji RB, Xu WR, Jin JH and Qian H: Exosomal
hsa_circ_000200 as a potential biomarker and metastasis enhancer of
gastric cancer via miR-4659a/b-3p/HBEGF axis. Cancer Cell Int.
23:1512023. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang W, Wang J, Zhang X and Liu G: Serum
circSETDB1 is a promising biomarker for predicting response to
platinum-taxane-combined chemotherapy and relapse in high-grade
serous ovarian cancer. Onco Targets Ther. 12:7451–7457. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Xu C, Jun E, Okugawa Y, Toiyama Y,
Borazanci E, Bolton J, Taketomi A, Kim SC, Shang D, Von Hoff D, et
al: A circulating panel of circRNA biomarkers for the noninvasive
and early detection of pancreatic ductal adenocarcinoma.
Gastroenterology. 166:178–190.e16. 2024. View Article : Google Scholar
|
|
19
|
Takahashi H, Ohigashi H, Gotoh K,
Marubashi S, Yamada T, Murata M, Ioka T, Uehara H, Yano M and
Ishikawa O: Preoperative gemcitabine-based chemoradiation therapy
for resectable and borderline resectable pancreatic cancer. Ann
Surg. 258:1040–1050. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Von Hoff DD, Ervin T, Arena FP, Chiorean
EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, et
al: Increased survival in pancreatic cancer with nab-paclitaxel
plus gemcitabine. N Engl J Med. 369:1691–1703. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Burris H and Storniolo AM: Assessing
clinical benefit in the treatment of pancreas cancer: Gemcitabine
compared to 5-fluorouracil. Eur J Cancer. 33(Suppl 1): S18–S22.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chen M, Liu X, Lu J, Teng H, Yu C, Liu Y
and Zheng Y: Dysregulation of the circ_0087502/miR-1179/TGFBR2
pathway supports gemcitabine resistance in pancreatic cancer.
Cancer Biol Ther. 24:22585662023. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lu Y, Zhou S, Cheng G, Ruan Y, Tian Y, Lv
K, Han S and Zhou X: CircLMTK2 silencing attenuates gemcitabine
resistance in pancreatic cancer by sponging miR-485-5p and to
target PAK1. J Oncol. 2022:19115922022. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Goan YG, Zhou B, Hu E, Mi S and Yen Y:
Overexpression of ribonucleotide reductase as a mechanism of
resistance to 2,2-difluorodeoxycytidine in the human KB cancer cell
line. Cancer Res. 59:4204–4207. 1999.PubMed/NCBI
|
|
25
|
Nakahira S, Nakamori S, Tsujie M,
Takahashi Y, Okami J, Yoshioka S, Yamasaki M, Marubashi S, Takemasa
I, Miyamoto A, et al: Involvement of ribonucleotide reductase M1
subunit overexpression in gemcitabine resistance of human
pancreatic cancer. Int J Cancer. 120:1355–1363. 2007. View Article : Google Scholar
|
|
26
|
Oyama K, Iwagami Y, Kobayashi S, Sasaki K,
Yamada D, Tomimaru Y, Noda T, Asaoka T, Takahashi H, Tanemura M, et
al: Removal of gemcitabine-induced senescent cancer cells by
targeting glutaminase1 improves the therapeutic effect in
pancreatic ductal adenocarcinoma. Int J Cancer. 154:912–925. 2024.
View Article : Google Scholar
|
|
27
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
28
|
Scherbakov AM, Vorontsova SK, Khamidullina
AI, Mrdjanovic J, Andreeva OE, Bogdanov FB, Salnikova DI, Jurisic
V, Zavarzin IV and Shirinian VZ: Novel pentacyclic derivatives and
benzylidenes of the progesterone series cause anti-estrogenic and
antiproliferative effects and induce apoptosis in breast cancer
cells. Invest New Drugs. 41:142–152. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Radenković N, Milutinović M, Nikodijević
D, Jovankić J and Jurišić V: Sample preparation of adherent cell
lines for flow cytometry: Protocol Optimization-our experience with
SW-480 colorectal cancer cell line. Indian J Clin Biochem.
40:74–79. 2025. View Article : Google Scholar
|
|
30
|
Ueda H, Takahashi H, Kobayashi S, Kubo M,
Sasaki K, Iwagami Y, Yamada D, Tomimaru Y, Asaoka T, Noda T, et al:
miR-6855-5p enhances radioresistance and promotes migration of
pancreatic cancer by inducing Epithelial-mesenchymal transition via
suppressing FOXA1: Potential of plasma exosomal miR-6855-5p as an
indicator of radiosensitivity in patients with pancreatic cancer.
Ann Surg Oncol. 32:720–735. 2025. View Article : Google Scholar
|
|
31
|
Taylor SC, Berkelman T, Yadav G and
Hammond M: A defined methodology for reliable quantification of
Western blot data. Mol Biotechnol. 55:217–226. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Dudekula DB, Panda AC, Grammatikakis I, De
S, Abdelmohsen K and Gorospe M: CircInteractome: A web tool for
exploring circular RNAs and their interacting proteins and
microRNAs. RNA Biol. 13:34–42. 2016. View Article : Google Scholar :
|
|
33
|
National Comprehensive Cancer Network
(NCCN) guidelines. (Pancreatic Adenocarcinoma (version 1.2023)).
Available at: https://www.nccn.org/guidelines/category_1. Accessed
June 12, 2023
|
|
34
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar
|
|
35
|
Oettle H, Neuhaus P, Hochhaus A, Hartmann
JT, Gellert K, Ridwelski K, Niedergethmann M, Zulke C, Fahlke J,
Arning MB, et al: Adjuvant chemotherapy with gemcitabine and
long-term outcomes among patients with resected pancreatic cancer:
The CONKO-001 randomized trial. JAMA. 310:1473–1481. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Uesaka K, Boku N, Fukutomi A, Okamura Y,
Konishi M, Matsumoto I, Kaneoka Y, Shimizu Y, Nakamori S, Sakamoto
H, et al: Adjuvant chemotherapy of S-1 versus gemcitabine for
resected pancreatic cancer: A phase 3, open-label, randomised,
non-inferiority trial (JASPAC 01). Lancet. 388:248–257. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Frese KK, Neesse A, Cook N, Bapiro TE,
Lolkema MP, Jodrell DI and Tuveson DA: nab-Paclitaxel potentiates
gemcitabine activity by reducing cytidine deaminase levels in a
mouse model of pancreatic cancer. Cancer Discov. 2:260–269. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wang Z, Li Y, Ahmad A, Banerjee S, Azmi
AS, Kong D and Sarkar FH: Pancreatic cancer: Understanding and
overcoming chemoresistance. Nat Rev Gastroenterol Hepatol. 8:27–33.
2011. View Article : Google Scholar
|
|
39
|
Rajabpour A, Rajaei F and Teimoori-Toolabi
L: Molecular alterations contributing to pancreatic cancer
chemoresistance. Pancreatology. 17:310–320. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Mackey JR, Mani RS, Selner M, Mowles D,
Young JD, Belt JA, Crawford CR and Cass CE: Functional nucleoside
transporters are required for gemcitabine influx and manifestation
of toxicity in cancer cell lines. Cancer Res. 58:4349–4357.
1998.PubMed/NCBI
|
|
41
|
Ohhashi S, Ohuchida K, Mizumoto K, Fujita
H, Egami T, Yu J, Toma H, Sadatomi S, Nagai E and Tanaka M:
Down-regulation of deoxycytidine kinase enhances acquired
resistance to gemcitabine in pancreatic cancer. Anticancer Res.
28:2205–2212. 2008.PubMed/NCBI
|
|
42
|
Ono H, Murase Y, Yamashita H, Kato T,
Asano D, Ishikawa Y, Watanabe S, Ueda H, Akahoshi K, Ogawa K, et
al: RRM1 is mediated by histone acetylation through gemcitabine
resistance and contributes to invasiveness and ECM remodeling in
pancreatic cancer. Int J Oncol. 62:512023. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Iwagami Y, Eguchi H, Nagano H, Akita H,
Hama N, Wada H, Kawamoto K, Kobayashi S, Tomokuni A, Tomimaru Y, et
al: miR-320c regulates gemcitabine-resistance in pancreatic cancer
via SMARCC1. Br J Cancer. 109:502–511. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Hasegawa S, Eguchi H, Nagano H, Konno M,
Tomimaru Y, Wada H, Hama N, Kawamoto K, Kobayashi S, Nishida N, et
al: MicroRNA-1246 expression associated with CCNG2-mediated
chemoresistance and stemness in pancreatic cancer. Br J Cancer.
111:1572–1580. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
De Sousa Cavalcante L and Monteiro G:
Gemcitabine: Metabolism and molecular mechanisms of action,
sensitivity and chemoresistance in pancreatic cancer. Eur J
Pharmacol. 741:8–16. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Zhang L, Li J, Zong L, Chen X, Chen K,
Jiang Z, Nan L, Li X, Li W, Shan T, et al: Reactive oxygen species
and targeted therapy for pancreatic cancer. Oxid Med Cell Longev.
2016:16167812016. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Prudner BC, Rathore R, Robinson AM, Godec
A, Chang SF, Hawkins WG, Hirbe AC and Van Tine BA: Arginine
starvation and docetaxel induce c-Myc-Driven hENT1 surface
expression to overcome gemcitabine resistance in ASS1-Negative
tumors. Clin Cancer Res. 25:5122–5134. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Hioki M, Shimada T, Yuan T, Nakanishi T,
Tajima H, Yamazaki M, Yokono R, Takabayashi M, Sawamoto K, Akashita
G, et al: Contribution of equilibrative nucleoside transporters 1
and 2 to gemcitabine uptake in pancreatic cancer cells. Biopharm
Drug Dispos. 39:256–264. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Greenhalf W, Ghaneh P, Neoptolemos JP,
Palmer DH, Cox TF, Lamb RF, Garner E, Campbell F, Mackey JR,
Costello E, et al: Pancreatic cancer hENT1 expression and survival
from gemcitabine in patients from the ESPAC-3 trial. J Natl Cancer
Inst. 106:djt3472014. View Article : Google Scholar
|
|
50
|
Farrell JJ, Elsaleh H, Garcia M, Lai R,
Ammar A, Regine WF, Abrams R, Benson AB, Macdonald J, Cass CE, et
al: Human equilibrative nucleoside transporter 1 levels predict
response to gemcitabine in patients with pancreatic cancer.
Gastroenterology. 136:187–195. 2009. View Article : Google Scholar
|
|
51
|
Aughton K, Elander NO, Evans A, Jackson R,
Campbell F, Costello E, Halloran CM, Mackey JR, Scarfe AG, Valle
JW, et al: hENT1 predicts benefit from gemcitabine in pancreatic
cancer but only with low CDA mRNA. Cancers (Basel). 13:57582021.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Gupta R, Arora K, Mehrotra Arora N and
Kundu P: Significance of VLPs in Vlp-circRNA vaccines: A vaccine
candidate or delivery vehicle? RNA Biol. 21:17–28. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Patel M, Singh P, Gandupalli L and Gupta
R: Identification and evaluation of Survival-associated common
chemoresistant genes in cancer. Biomed Biotechnol Res J. 8:320–327.
2024. View Article : Google Scholar
|
